1Fattom A, Horwith G, Fuller S, et al. Development of StaphVAX, a polysaceharide conjugate vaccine against S. aureus infection: From the lab bench to phase Ⅲ clinical trials. Vaccine ,2004,22:880 -887.
2von Eiff C ,Taylor KL, Mellmann A, et al. Distribution of capsular and surface polysaccharide serotypes of Staphylococcus aureus. Diagn Microbiol Infect Dis ,2007,58:297 - 302.
3Hoen B, Paul-Dauphin A, Hestin D, et al. EPIBACDIAL: A muhicenter prospective study of risk factors for baeteremia in chronic hemodialysis patients. J Am Soc Nephrol, 1998,9 (5) :869 - 876.
4Diskin CJ,Stokes TJ,Dansby LM,et al. Is systemic heparin a risk factor for catheter-related sepsis in dialysis pat ents? An evaluation of various biofilm and traditional risk factors. Nephron Clin Pract,2007,107:c128-c132.
5TeehanGS, Bahdouch D, Ruthazer R, et al. Iron storage indices: Novel predictors of bacteremia in hemodialysis patients initiating intravenous iron therapy. Clin Infect Dis,2004,38:1090- 1094.
6ShroffGR,Skeans M, Herzog CA. Outcomes of renal transplant and waiting list patients with baeterlal endocarditis in the United States. Nephrol Dial Transplant,2005,23:2381 -2385.
7Taylor G, Gravel D, Johnston L, et al. Incidence of bloodstream infection in multicenter inception cohorts of hemodialysis patients. Am J Infect Control, 2004,32:155 -160.
8VandenBergh MF, Yzerman EP,van Belkum A, et al. Follow-up of Staphylococcus aureus nasal carriage after 8 years: Redefining the persistent carrier state. J Clin Microbiol, 1999,37:3133 -3140.
9Wertheim HF,Melles DC, Vos MC,et al. The role of nasal carriage in Staphylococcus aureus infections. Lancet hffect Dis,2005,5:751 -762.
10Wertheim HF,Vos MC,Ott A,et al. Risk and outcome of nosocomial Staphylococcus aureus bactcraemia in nasal carriers non-carriers. Lancet ,2004,364:703 - 705.
